FDA Adding More Pediatric Data To Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA divisions will be more aggressive in requiring pediatric data be included in labeling following recommendation by Office of New Drugs Director Jenkins. However, the added language in labeling will not necessarily clarify whether a drug is safe for use in children, Office of Pediatric Therapeutics Director Murphy notes.
You may also be interested in...
Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis
FDA’s Pediatric Advisory Committee says the easiest short-term remedy for improving the quality of the agency’s adverse event reporting system would be claims database analysis, although the best method would be population-based active surveillance.
Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis
FDA’s Pediatric Advisory Committee says the easiest short-term remedy for improving the quality of the agency’s adverse event reporting system would be claims database analysis, although the best method would be population-based active surveillance.
FDA Approves Antidepressant "Black Box" Class Labeling
The revised labeling should be available on manufacturers' web pages within two weeks and on all products within 30 days, FDA says. Medication Guides should be available to pharmacists by Jan. 31, the agency says.